{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:20:29Z","timestamp":1781104829698,"version":"3.54.1"},"reference-count":173,"publisher":"Bentham Science Publishers Ltd.","issue":"31","funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["ISRM\/11\/(19)\/2017"],"award-info":[{"award-number":["ISRM\/11\/(19)\/2017"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004541","name":"Ministry of Human Resource Development","doi-asserted-by":"publisher","award":["F.24-51 \/ 2014 -U"],"award-info":[{"award-number":["F.24-51 \/ 2014 -U"]}],"id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["SR\/PURSE Phase 2\/38"],"award-info":[{"award-number":["SR\/PURSE Phase 2\/38"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["SR\/FST\/LSI - 667\/2016"],"award-info":[{"award-number":["SR\/FST\/LSI - 667\/2016"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology","doi-asserted-by":"publisher","award":["BT\/PR8138\/BID\/7\/458\/2013"],"award-info":[{"award-number":["BT\/PR8138\/BID\/7\/458\/2013"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,11,14]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Today, HIV-1 infection has become an extensive problem to public health and a greater challenge to all working researchers throughout the world. Since the beginning of HIV-1 virus, several antiviral therapeutic agents have been developed at various stages to combat HIV-1 infection. But, many of antiviral drugs are on the platform of drug resistance and toxicology issues, needs an urgent constructive investigation for the development of productive and protective therapeutics to make an improvement of individual life suffering with viral infection. As developing a novel agent is very costly, challenging and time taking route in the recent times.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>The review summarized about the modern approaches of computational aided drug discovery to developing a novel inhibitor within a short period of time and less cost.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The outcome suggests on the premise of reported information that the computational drug discovery is a powerful technology to design a defensive and fruitful therapeutic agents to combat HIV-1 infection and recover the lifespan of suffering one.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Based on survey of the reported information, we concluded that the current computational approaches is highly supportive in the progress of drug discovery and controlling the viral infection.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1381612825666190911160244","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T13:25:40Z","timestamp":1568899540000},"page":"3390-3405","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Current Computational Approaches for the Development of Anti-HIV Inhibitors: An Overview"],"prefix":"10.2174","volume":"25","author":[{"given":"Umesh","family":"Panwar","sequence":"first","affiliation":[{"name":"Computer Aided Drug Design and Molecular Modeling Lab, Department of Bioinformatics, Alagappa University, Karaikudi-630 004, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishwar","family":"Chandra","sequence":"additional","affiliation":[{"name":"Computer Aided Drug Design and Molecular Modeling Lab, Department of Bioinformatics, Alagappa University, Karaikudi-630 004, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrabose","family":"Selvaraj","sequence":"additional","affiliation":[{"name":"CEITEC - Central European Institute of Technology, Masaryk University, Kamenice, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev K.","family":"Singh","sequence":"additional","affiliation":[{"name":"Computer Aided Drug Design and Molecular Modeling Lab, Department of Bioinformatics, Alagappa University, Karaikudi-630 004, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006841","volume":"1","author":"Sharp P.M.","year":"2011","unstructured":"Sharp P.M.; Hahn B.H.; Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 2011,1(1)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1002\/eji.200737441","volume":"37","author":"Greene W.C.","year":"2007","unstructured":"Greene W.C.; A history of AIDS: looking back to see ahead. Eur J Immunol 2007,37(S1)(Suppl. 1),S94-S102","journal-title":"Eur J Immunol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(85)92556-5","volume":"2","author":"Barin F","year":"1985","unstructured":"Barin F; M\u2019Boup S; Denis F; Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa. Lancet 1985,2(8469-70),1387-9","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/0470020970.ch25","author":"Weiss R.A.","year":"2004","unstructured":"Weiss R.A.; Dalgleish A.G.; Loveday C.; Pillay D.; Human Immunodeficiency Viruses Principles and Practice of Clinical Virology 2004,721-757","journal-title":"Human Immunodeficiency Viruses Principles and Practice of Clinical Virology"},{"key":"ref=5","first-page":"1881","author":"Luciw P.A.","year":"1996","unstructured":"Luciw P.A.; Human immunodeficiency viruses and their replication Virology 1996,1881-1952","journal-title":"Human immunodeficiency viruses and their replication Virology"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","volume":"85","author":"Broder S.","year":"2010","unstructured":"Broder S.; The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic. Antiviral Res 2010,85(1),1-18","journal-title":"Antiviral Res"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.1596\/978-1-4648-0524-0_ch2","author":"Danforth K.","year":"2017","unstructured":"Danforth K.; Granich R.; Wiedeman D.; Baxi S.; Padian N.; Global Mortality and morbidity of HIV\/AIDS Source Major Infectious Diseases 2017","journal-title":"Global Mortality and morbidity of HIV\/AIDS Source Major Infectious Diseases"},{"key":"ref=8","unstructured":"HIV Treatment Overview [homepage on the Internet] HIVgov [updated 2019 March 29] Available from:"},{"key":"ref=9","first-page":"1405","volume":"9","author":"Bisht N.","year":"2018","unstructured":"Bisht N.; Singh B.K.; Role of computer aided drug design in drug development and drug discovery. Int J Pharm Sci Res 2018,9,1405-1415","journal-title":"Int J Pharm Sci Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.22270\/jddt.v8i5.1894","volume":"8","author":"Surabhi S.","year":"2018","unstructured":"Surabhi S.; Singh B.; Computer aided drug design: an overview. J Drug Deliv Ther 2018,8,504-509","journal-title":"J Drug Deliv Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10461-010-9787-8","volume":"15","author":"Eaton J.W.","year":"2011","unstructured":"Eaton J.W.; Hallett T.B.; Garnett G.P.; Concurrent sexual partnerships and primary HIV infection: a critical interaction. AIDS Behav 2011,15(4),687-692","journal-title":"AIDS Behav"},{"key":"ref=12","unstructured":"World Health Organization [homepage on the Internet]. HIV\/AIDS key facts [cited 2019 Jul 17] Available from:","journal-title":"key facts [cited 2019 Jul 17]"},{"key":"ref=13","unstructured":"UNAIDS [homepage on the Internet]. Global HIV"},{"key":"ref=14","unstructured":"World Health Organization [homepage on the Internet]. Global summary of the HIV\/AIDS epidemic Available from:"},{"key":"ref=15","unstructured":"Global information and education on HIV and AIDS [homepage on the Internet]. HIV and AIDS in India Available from:"},{"key":"ref=16","first-page":"82","volume":"7","author":"Al-Jabri A.A.","year":"2007","unstructured":"Al-Jabri A.A.; Mechanisms of host resistance against HIV infection and progression to AIDS. Sultan Qaboos Univ Med J 2007,7(2),82-96","journal-title":"Sultan Qaboos Univ Med J"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1023\/A:1021070512287","volume":"26","author":"Freed E.O.","year":"2001","unstructured":"Freed E.O.; HIV-1 replication. Somat Cell Mol Genet 2001,26(1-6),13-33","journal-title":"Somat Cell Mol Genet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13337-010-0001-4","volume":"21","author":"Seth P.","year":"2010","unstructured":"Seth P.; Evolution of HIV-1 in India. Indian J Virol 2010,21(1),3-7","journal-title":"Indian J Virol"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090845","volume":"9","author":"Jacobs G.B.","year":"2014","unstructured":"Jacobs G.B.; Wilkinson E.; Isaacs S.; HIV-1 subtypes B and C unique recombinant forms (URFs) and transmitted drug resistance identified in the Western Cape Province, South Africa. PLoS One 2014,9(6)","journal-title":"PLoS One"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1128\/JVI.74.3.1234-1240.2000","volume":"74","author":"Jetzt A.E.","year":"2000","unstructured":"Jetzt A.E.; Yu H.; Klarmann G.J.; Ron Y.; Preston B.D.; Dougherty J.P.; High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol 2000,74(3),1234-1240","journal-title":"J Virol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/biom6010002","volume":"6","author":"Ryan E.L.","year":"2016","unstructured":"Ryan E.L.; Hollingworth R.; Grand R.J.; Activation of the DNA damage response by RNA viruses. Biomolecules 2016,6(1),2","journal-title":"Biomolecules"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1128\/MMBR.63.4.836-843.1999","volume":"63","author":"Hindmarsh P.","year":"1999","unstructured":"Hindmarsh P.; Leis J.; Retroviral DNA integration. Microbiol Mol Biol Rev 1999,63(4),836-843","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref=23","unstructured":"Centers for Diesease Control adn Prevention [homepage on the Internet]. HIV Transmission Available from:"},{"key":"ref=24","unstructured":"AIDSinfo [homepage on the Internet]. The HIV Life Cycle Available from:"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.mib.2010.06.002","volume":"13","author":"Cunningham A.L.","year":"2010","unstructured":"Cunningham A.L.; Donaghy H.; Harman A.N.; Kim M.; Turville S.G.; Manipulation of dendritic cell function by viruses. Curr Opin Microbiol 2010,13(4),524-529","journal-title":"Curr Opin Microbiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nature12940","volume":"505","author":"Doitsh G.","year":"2014","unstructured":"Doitsh G.; Galloway N.L.; Geng X.; Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014,505(7484),509-514","journal-title":"Nature"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.3390\/v4113020","volume":"4","author":"Garg H.","year":"2012","unstructured":"Garg H.; Mohl J.; Joshi A.; HIV-1 induced bystander apoptosis. Viruses 2012,4(11),3020-3043","journal-title":"Viruses"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrmicro2747","volume":"10","author":"Engelman A.","year":"2012","unstructured":"Engelman A.; Cherepanov P.; The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol 2012,10(4),279-290","journal-title":"Nat Rev Microbiol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000445852","volume":"43","author":"Blood G.A.","year":"2016","unstructured":"Blood G.A.; Human immunodeficiency virus (HIV). Transfus Med Hemother 2016,43(3),203-222","journal-title":"Transfus Med Hemother"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.chom.2008.04.008","volume":"3","author":"Malim M.H.","year":"2008","unstructured":"Malim M.H.; Emerman M.; HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe 2008,3(6),388-398","journal-title":"Cell Host Microbe"},{"key":"ref=31","first-page":"2107","author":"Freed EO","unstructured":"Freed EO; Martin MA; HIVs and their replication. Fields Virology ,2107-86","journal-title":"Fields Virology"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006916","volume":"2","author":"Karn J.","year":"2012","unstructured":"Karn J.; Stoltzfus C.M.; Transcriptional and posttranscriptional regulation of HIV-1 gene expression. Cold Spring Harb Perspect Med 2012,2(2)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1128\/AAC.01537-09","volume":"54","author":"Donahue D.A.","year":"2010","unstructured":"Donahue D.A.; Sloan R.D.; Kuhl B.D.; Bar-Magen T.; Schader S.M.; Wainberg M.A.; Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother 2010,54(3),1047-1054","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006866","volume":"2","author":"Wilen C.B.","year":"2012","unstructured":"Wilen C.B.; Tilton J.C.; Doms R.W.; HIV: cell binding and entry. Cold Spring Harb Perspect Med 2012,2(8)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/31405","volume":"393","author":"Kwong P.D.","year":"1998","unstructured":"Kwong P.D.; Wyatt R.; Robinson J.; Sweet R.W.; Sodroski J.; Hendrickson W.A.; Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998,393(6686),648-659","journal-title":"Nature"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1083\/jcb.200203150","volume":"159","author":"McDonald D.","year":"2002","unstructured":"McDonald D.; Vodicka M.A.; Lucero G.; Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 2002,159(3),441-452","journal-title":"J Cell Biol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12977-016-0292-7","volume":"13","author":"Cosnefroy O.","year":"2016","unstructured":"Cosnefroy O.; Murray P.J.; Bishop K.N.; HIV-1 capsid uncoating initiates after the first strand transfer of reverse transcription. Retrovirology 2016,13(1),58","journal-title":"Retrovirology"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006890","volume":"2","author":"Craigie R.","year":"2012","unstructured":"Craigie R.; Bushman F.D.; HIV DNA integration. Cold Spring Harb Perspect Med 2012,2(7)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1631\/jzus.B1400059","volume":"15","author":"Liu R.D.","year":"2014","unstructured":"Liu R.D.; Wu J.; Shao R.; Xue Y.H.; Mechanism and factors that control HIV-1 transcription and latency activation. J Zhejiang Univ Sci B 2014,15(5),455-465","journal-title":"J Zhejiang Univ Sci B"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.3390\/v7082822","volume":"7","author":"Rojas-Araya B.","year":"2015","unstructured":"Rojas-Araya B.; Ohlmann T.; Soto-Rifo R.; Translational control of the HIV unspliced genomic RNA. Viruses 2015,7(8),4326-4351","journal-title":"Viruses"},{"key":"ref=41","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a013250","volume":"5","author":"Inoue T.","year":"2013","unstructured":"Inoue T.; Tsai B.; How viruses use the endoplasmic reticulum for entry, replication, and assembly. Cold Spring Harb Perspect Biol 2013,5(1)","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrmicro3490","volume":"13","author":"Freed E.O.","year":"2015","unstructured":"Freed E.O.; HIV-1 assembly, release and maturation. Nat Rev Microbiol 2015,13(8),484-496","journal-title":"Nat Rev Microbiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2045-3701-2-32","volume":"2","author":"Yang H.","year":"2012","unstructured":"Yang H.; Nkeze J.; Zhao R.Y.; Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy. Cell Biosci 2012,2(1),32","journal-title":"Cell Biosci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.1002\/jcb.28181","volume":"120","author":"Nayak C.","year":"2019","unstructured":"Nayak C.; Chandra I.; Singh S.K.; An in silico pharmacological approach toward the discovery of potent inhibitors to combat drug resistance HIV-1 protease variants. J Cell Biochem 2019,120(6),9063-9081","journal-title":"J Cell Biochem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1007\/s00044-011-9941-5","volume":"21","author":"Selvaraj C.","year":"2012","unstructured":"Selvaraj C.; Singh S.K.; Tripathi S.K.; Reddy K.K.; Rama M.; In silico screening of indinavir-based compounds targeting proteolytic activity in HIV PR: binding pocket fit approach. Med Chem Res 2012,21,4060-4068","journal-title":"Med Chem Res"},{"key":"ref=46","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007161","volume":"2","author":"Arts E.J.","year":"2012","unstructured":"Arts E.J.; Hazuda D.J.; HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012,2(4)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=47","author":"Kemnic T.R.","year":"2019","unstructured":"Kemnic T.R.; Gulick P.G.; HIV antiretroviral therapy StatPearls Treasure Island 2019","journal-title":"HIV antiretroviral therapy StatPearls Treasure Island"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.apsb.2018.01.012","volume":"8","author":"Zhang X.","year":"2018","unstructured":"Zhang X.; Anti-retroviral drugs: current state and development in the next decade. Acta pharma sin B 2018,8,131-6","journal-title":"Acta pharma sin B"},{"key":"ref=49","unstructured":"A Timeline of HIV and AIDS [homepage on the Internet] Available from:"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4049\/jimmunol.109.1.129","volume":"109","author":"Engvall E.","year":"1972","unstructured":"Engvall E.; Perlmann P.; Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol 1972,109(1),129-135","journal-title":"J Immunol"},{"key":"ref=51","first-page":"157","volume":"35","year":"2006","unstructured":"Rapid HIV test kits. Health Devices 2006,35(5),157-177","journal-title":"Health Devices"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.ajog.2005.07.001","volume":"193","author":"Doyle N.M.","year":"2005","unstructured":"Doyle N.M.; Levison J.E.; Gardner M.O.; Rapid HIV versus enzyme-linked immunosorbent assay screening in a low-risk Mexican American population presenting in labor: a cost-effectiveness analysis. Am J Obstet Gynecol 2005,193(3 Pt 2),1280-1285","journal-title":"Am J Obstet Gynecol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1128\/CVI.00053-16","volume":"23","author":"Alexander T.S.","year":"2016","unstructured":"Alexander T.S.; Human immunodeficiency virus diagnostic testing: 30 years of evolution. Clin Vaccine Immunol 2016,23(4),249-253","journal-title":"Clin Vaccine Immunol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/106002809202600217","volume":"26","author":"Amsden G.W.","year":"1992","unstructured":"Amsden G.W.; Kowalsky S.F.; Morse G.D.; Trimetrexate for Pneumocystis carinii pneumonia in patients with AIDS. Ann Pharmacother 1992,26(2),218-226","journal-title":"Ann Pharmacother"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1089\/apc.1989.3.16","volume":"3","author":"Moussalli C.","year":"1989","unstructured":"Moussalli C.; Alpha interferon: a new treatment for AIDS-related Kaposi\u2019s sarcoma. AIDS Patient Care 1989,3(3),16","journal-title":"AIDS Patient Care"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1365-2141.1991.tb08124.x","volume":"79","author":"Mitsuyasu R.T.","year":"1991","unstructured":"Mitsuyasu R.T.; Interferon alpha in the treatment of AIDS-related Kaposi\u2019s sarcoma. Br J Haematol 1991,79(Suppl. 1),69-73","journal-title":"Br J Haematol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacbts.2018.02.001","volume":"3","author":"Van Norman G.A.","year":"2018","unstructured":"Van Norman G.A.; Expanding patient access to investigational new drugs: overview of intermediate and widespread treatment investigational new drugs, and emergency authorization in public health emergencies. JACC Basic Transl Sci 2018,3(3),403-414","journal-title":"JACC Basic Transl Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1056\/NEJM199609053351007","volume":"335","author":"Crumpacker C.S.","year":"1996","unstructured":"Crumpacker C.S.; Ganciclovir. N Engl J Med 1996,335(10),721-729","journal-title":"N Engl J Med"},{"key":"ref=59","unstructured":"U.S. National Library of Medicine [homepage on the Internet]. A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients with Immediately Sight-Threatening CMV Retinitis Available from:"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1001\/archinte.1989.00390110018005","volume":"149","author":"Young F.E.","year":"1989","unstructured":"Young F.E.; Nightingale S.L.; Cooper E.C.; Trapnell C.B.; Aerosolized pentamidine. Approved for HIV-infected individuals at high risk for Pneumocystis carinii pneumonia. Arch Intern Med 1989,149(11),2412-2413","journal-title":"Arch Intern Med"},{"key":"ref=61","unstructured":"HIV InSite [homepage on the Internet]. Zidovudine (Retrovir) Available from:"},{"key":"ref=62","unstructured":"U.S. National Library of Medicine [homepage on the Internet]. A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine Available from:"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/106002809302700416","volume":"27","author":"Shelton M.J.","year":"1993","unstructured":"Shelton M.J.; O\u2019Donnell A.M.; Morse G.D.; Zalcitabine. Ann Pharmacother 1993,27(4),480-489","journal-title":"Ann Pharmacother"},{"key":"ref=64","unstructured":"NIH U.S. National Library of Medicine [homepage on the Internet]. Clinical Alert: Important Therapeutic Information on Treatment of HIV Infection in HIV-Infected Patients Who Are Intolerant of or Have Failed Zidovudine Therapy Available from:"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","volume":"85","author":"Broder S.","year":"2010","unstructured":"Broder S.; The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic. Antiviral Res 2010,85(1),1-18","journal-title":"Antiviral Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.apsb.2018.01.012","volume":"8","author":"Zhang X.","year":"2018","unstructured":"Zhang X.; Anti-retroviral drugs: current state and development in the next decade. Acta Pharm Sin B 2018,8(2),131-136","journal-title":"Acta Pharm Sin B"},{"key":"ref=67","first-page":"1","author":"James J.S.","year":"1995","unstructured":"James J.S.; Lamivudine (3TC) approved for combination use with AZT. AIDS Treat News 1995(236),1-5","journal-title":"AIDS Treat News"},{"key":"ref=68","first-page":"1","author":"James J.S.","year":"1995","unstructured":"James J.S.; Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers. AIDS Treat News 1995(237),1-2","journal-title":"AIDS Treat News"},{"key":"ref=69","first-page":"4","author":"Folkers G.","year":"1996","unstructured":"Folkers G.; Two new protease inhibitors approved by FDA. NIAID AIDS Agenda 1996,4-5","journal-title":"NIAID AIDS Agenda"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1046\/j.1537-2995.2001.41050643.x","volume":"41","author":"Yang Y.","year":"2001","unstructured":"Yang Y.; Lamendola M.H.; Mendoza M.; Performance characteristics of the COBAS AmpliScreen HIV-1 test, version 1.5, an assay designed for screening plasma mini-pools. Transfusion 2001,41(5),643-651","journal-title":"Transfusion"},{"key":"ref=71","first-page":"10","author":"Bowersox J.","year":"1996","unstructured":"Bowersox J.; Nevirapine approved by FDA. NIAID AIDS Agenda 1996,10","journal-title":"NIAID AIDS Agenda"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1517\/17425255.2.2.285","volume":"2","author":"Olmo M.","year":"2006","unstructured":"Olmo M.; Podzamczer D.; A review of nelfinavir for the treatment of HIV infection. Expert Opin Drug Metab Toxicol 2006,2(2),285-300","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=73","first-page":"70","volume":"12","year":"1997","unstructured":"Delavirdine gets FDA approval. Aids Alert 1997,12(6),70","journal-title":"Aids Alert"},{"key":"ref=74","first-page":"579","volume":"3","author":"Portsmouth S.D.","year":"2007","unstructured":"Portsmouth S.D.; Scott C.J.; The renaissance of fixed dose combinations: combivir. Ther Clin Risk Manag 2007,3(4),579-583","journal-title":"Ther Clin Risk Manag"},{"key":"ref=75","first-page":"3","volume":"12","author":"Highleyman L.","year":"1999","unstructured":"Highleyman L.; Amprenavir (Agenerase) receives FDA approval. BETA 1999,12(2),3","journal-title":"BETA"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.288.2.222","volume":"288","author":"Yeni P.G.","year":"2002","unstructured":"Yeni P.G.; Hammer S.M.; Carpenter C.C.; Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002,288(2),222-235","journal-title":"JAMA"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.idc.2014.06.001","volume":"28","author":"Pau A.K.","year":"2014","unstructured":"Pau A.K.; George J.M.; Antiretroviral therapy: current drugs. Infect Dis Clin North Am 2014,28(3),371-402","journal-title":"Infect Dis Clin North Am"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/TCRM.S3285","volume":"4","author":"Chandwani A.","year":"2008","unstructured":"Chandwani A.; Shuter J.; Lopinavir\/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 2008,4(5),1023-1033","journal-title":"Ther Clin Risk Manag"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2165\/00003495-200767100-00006","volume":"67","author":"Moreno S.","year":"2007","unstructured":"Moreno S.; Hern\u00e1ndez B.; Dronda F.; Didanosine enteric-coated capsule: current role in patients with HIV-1 infection. Drugs 2007,67(10),1441-1462","journal-title":"Drugs"},{"key":"ref=80","first-page":"701","volume":"10","year":"2000","unstructured":"FDA approves Trizivir for HIV infection. AIDS Read 2000,10(12),701","journal-title":"AIDS Read"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2165\/00126839-200405030-00004","volume":"5","year":"2004","unstructured":"Emtricitabine\/tenofovir disoproxil fumarate. Drugs R D 2004,5(3),160-161","journal-title":"Drugs R D"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1128\/JCM.41.4.1586-1593.2003","volume":"41","author":"Grant R.M.","year":"2003","unstructured":"Grant R.M.; Kuritzkes D.R.; Johnson V.A.; Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol 2003,41(4),1586-1593","journal-title":"J Clin Microbiol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2217\/fvl.10.89","volume":"6","author":"Achenbach C.J.","year":"2011","unstructured":"Achenbach C.J.; Darin K.M.; Murphy R.L.; Katlama C.; Atazanavir\/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol 2011,6(2),157-177","journal-title":"Future Virol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1021\/acs.accounts.6b00274","volume":"49","author":"Liotta D.C.","year":"2016","unstructured":"Liotta D.C.; Painter G.R.; Discovery and development of the anti-human immunodeficiency virus drug, emtricitabine (Emtriva, FTC). Acc Chem Res 2016,49(10),2091-2098","journal-title":"Acc Chem Res"},{"key":"ref=85","first-page":"641","volume":"3","author":"Streeck H.","year":"2007","unstructured":"Streeck H.; Rockstroh J.K.; Review of tipranavir in the treatment of drug-resistant HIV. Ther Clin Risk Manag 2007,3(4),641-651","journal-title":"Ther Clin Risk Manag"},{"key":"ref=86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140708","volume":"10","author":"Hao J.","year":"2015","unstructured":"Hao J.; Rodriguez-Monguio R.; Seoane-Vazquez E.; Fixed-dose combination drug approvals, patents and market exclusivities compared to single active ingredient pharmaceuticals. PLoS One 2015,10(10)","journal-title":"PLoS One"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4103\/0975-7406.80763","volume":"3","author":"Patel A.","year":"2011","unstructured":"Patel A.; Gandhi H.; Upaganlawar A.; Tesamorelin: a hope for ART-induced lipodystrophy. J Pharm Bioallied Sci 2011,3(2),319-320","journal-title":"J Pharm Bioallied Sci"},{"key":"ref=88","first-page":"18","volume":"19","author":"Daskalakis D.","year":"2011","unstructured":"Daskalakis D.; HIV diagnostic testing: evolving technology and testing strategies. Top Antivir Med 2011,19(1),18-22","journal-title":"Top Antivir Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/jac\/dks404","volume":"68","author":"Sharma M.","year":"2013","unstructured":"Sharma M.; Saravolatz L.D.; Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. J Antimicrob Chemother 2013,68(2),250-256","journal-title":"J Antimicrob Chemother"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/jac\/45.4.417","volume":"45","author":"Drake S.M.","year":"2000","unstructured":"Drake S.M.; NNRTIs-a new class of drugs for HIV. J Antimicrob Chemother 2000,45(4),417-420","journal-title":"J Antimicrob Chemother"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1073\/pnas.1720975115","volume":"115","author":"Sluis-Cremer N.","year":"2018","unstructured":"Sluis-Cremer N.; Future of nonnucleoside reverse transcriptase inhibitors. Proc Natl Acad Sci USA 2018,115(4),637-638","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","volume":"379","author":"Sax P.E.","year":"2012","unstructured":"Sax P.E.; DeJesus E.; Mills A.; Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012,379(9835),2439-2448","journal-title":"Lancet"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jiph.2015.04.020","volume":"8","author":"Kabbara W.K.","year":"2015","unstructured":"Kabbara W.K.; Ramadan W.H.; Emtricitabine\/rilpivirine\/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. J Infect Public Health 2015,8(5),409-417","journal-title":"J Infect Public Health"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1345\/aph.1R468","volume":"46","author":"Olin J.L.","year":"2012","unstructured":"Olin J.L.; Spooner L.M.; Klibanov O.M.; Elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Ann Pharmacother 2012,46(12),1671-1677","journal-title":"Ann Pharmacother"},{"key":"ref=95","first-page":"153","volume":"5","author":"Patel T.S.","year":"2013","unstructured":"Patel T.S.; Crutchley R.D.; Tucker A.M.; Cottreau J.; Garey K.W.; Crofelemer for the treatment of chronic diarrhea in patients living with HIV\/AIDS. HIV AIDS (Auckl) 2013,5,153-162","journal-title":"HIV AIDS (Auckl)"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/cid\/ciu221","volume":"59","author":"Osterholzer D.A.","year":"2014","unstructured":"Osterholzer D.A.; Goldman M.; Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection. Clin Infect Dis 2014,59(2),265-271","journal-title":"Clin Infect Dis"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/eri.11.157","volume":"10","author":"Lampiris H.W.","year":"2012","unstructured":"Lampiris H.W.; Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. Expert Rev Anti Infect Ther 2012,10(1),13-20","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=98","unstructured":"U.S. Food"},{"key":"ref=99","unstructured":"The Medical Letter [homepage on the Internet] Cobicistat (Tybost) and Combinations for HIV Available from:"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40121-016-0126-x","volume":"5","author":"Badowski M.E.","year":"2016","unstructured":"Badowski M.E.; P\u00e9rez S.E.; Biagi M.; Littler J.A.; New antiretroviral treatment for HIV. Infect Dis Ther 2016,5(3),329-352","journal-title":"Infect Dis Ther"},{"key":"ref=101","unstructured":"TheBodyPro For the HIV\/AIDS Work Force [homepage on the Internet]. An Overview of Prezcobix (Darunavir\/Cobicistat) Available from:"},{"key":"ref=102","unstructured":"Descovy and Odefsey: Gilead Sciences\u2019 Recently Approved TAFBased Products [homepage on the Internet] Available from:"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.2147\/DDDT.S147493","volume":"12","author":"Squillace N.","year":"2018","unstructured":"Squillace N.; Bozzi G.; Colella E.; Gori A.; Bandera A.; Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. Drug Des Devel Ther 2018,12,3635-3643","journal-title":"Drug Des Devel Ther"},{"key":"ref=104","unstructured":"MedScape [homepage on the Internet]. EC Clears Two New HIV Drugs (Pifeltro and Delstrigo) Available from:"},{"key":"ref=105","unstructured":"MPR The Right Dose of Information [homepage on the Internet]. Temixys Approved for the Treatment of HIV-1 Infection Available from:"},{"key":"ref=106","unstructured":"CenterWatch [homepage on the Internet]. Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) Available from:"},{"key":"ref=107","unstructured":"AIDSinfo [homepage on the Internet]. FDA-Approved HIV Medicines Available from:"},{"key":"ref=108","unstructured":"CATIE [homepage on the Internet]. New drugs, new hope and possible timelines Available from:"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/COH.0000000000000471","volume":"13","author":"Colombier M.A.","year":"2018","unstructured":"Colombier M.A.; Molina J.M.; Doravirine: a review. Curr Opin HIV AIDS 2018,13(4),308-314","journal-title":"Curr Opin HIV AIDS"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s40265-018-0993-4","volume":"78","author":"Deeks E.D.","year":"2018","unstructured":"Deeks E.D.; Doravirine: First Global Approval. Drugs 2018,78(15),1643-1650","journal-title":"Drugs"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12985-018-1050-3","volume":"15","author":"Luo A.","year":"2018","unstructured":"Luo A.; Jiang X.; Ren H.; Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV\/HIV coinfection: a meta-analysis. Virol J 2018,15(1),139","journal-title":"Virol J"},{"key":"ref=112","unstructured":"Drugs.Com Know more be sure [homepage on the Internet]. FDA Approves Dovato (dolutegravir\/lamivudine) for HIV-1 Infection Available from:"},{"key":"ref=113","unstructured":"U.S. Food"},{"key":"ref=114","first-page":"1026","volume":"3","author":"Vaidya K.A.","year":"2016","unstructured":"Vaidya K.A.; Kadam A.V.; Nema V.; Anti-Retroviral Drugs for HIV: Old and New. Austin J HIV AIDS Res 2016,3,1026","journal-title":"Austin J HIV AIDS Res"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"43","DOI":"10.14218\/JERP.2017.00025","volume":"3","author":"Panwar U.","year":"2018","unstructured":"Panwar U.; Singh S.K.; An overview on Zika Virus and the importance of computational drug discovery. J Expl Res Pharm 2018,3,43-51","journal-title":"J Expl Res Pharm"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-319-05122-2_3","volume":"4","author":"Sarkar S.","year":"2014","unstructured":"Sarkar S.; Nandi S.; QSAR modeling of HEPT compounds: an attempt to anti HIV drug design. J Comput Meth Mol Des 2014,4,15-25","journal-title":"J Comput Meth Mol Des"},{"key":"ref=117","volume":"1","author":"Imam SS","year":"2017","unstructured":"Imam SS; Gilani SJ; Computer aided drug design: a novel loom to drug discovery. Org Med Chem IJ 2017,1(4)","journal-title":"Org Med Chem IJ"},{"key":"ref=118","first-page":"118","volume":"4","author":"Sharma V.","year":"2014","unstructured":"Sharma V.; Kumar V.; Efficient way of drug designing: a comprehensive review on computational techniques. Bull Pharm Res 2014,4,118-123","journal-title":"Bull Pharm Res"},{"key":"ref=119","first-page":"3","volume":"1","author":"Wadood A.","year":"2013","unstructured":"Wadood A.; Ahmed N.; Shah L.; Ahmad A.; Hassan H.; Shams S.; OA drug design 2013,1,3-7","journal-title":"OA drug design"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.22271\/tpi.2017.v6.i9a.1246","volume":"6","author":"Sharma S.K.","year":"2017","unstructured":"Sharma S.K.; Sharma E.; Sharma Y.; A review: recent computational approaches in medicinal chemistry: computer aided drug designing and delivery. Pharm Innov 2017,6(5, Part A),5","journal-title":"Pharm Innov"},{"key":"ref=121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112783","volume":"20","author":"Batool M.","year":"2019","unstructured":"Batool M.; Ahmad B.; Choi S.; A structure-based drug discovery paradigm. Int J Mol Sci 2019,20(11)","journal-title":"Int J Mol Sci"},{"key":"ref=122","doi-asserted-by":"publisher","DOI":"10.2174\/0929867326666190409141016","author":"Mazanetz M.P.","year":"2019","unstructured":"Mazanetz M.P.; Goode C.H.F.; Chudyk E.I.; Ligand- and structure-based drug design and optimization using KNIME. Curr Med Chem In press2019","journal-title":"Curr Med Chem"},{"key":"ref=123","first-page":"82","volume":"4","author":"Salman M.","year":"2019","unstructured":"Salman M.; Ahmed S.; Nandi S.; QSAR and anticancer drug design on benzothienopyrimidinones as promising pim kinase inhibitors utilizing structural descriptors. Int J Quant Str-Prop Relation 2019,4,82-99","journal-title":"Int J Quant Str-Prop Relation"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/1062936X.2017.1419375","volume":"29","author":"Nandi S.","year":"2018","unstructured":"Nandi S.; Ahmed S.; Saxena A.K.; Combinatorial design and virtual screening of potent anti-tubercular fluoroquinolone and isothiazoloquinolone compounds utilizing QSAR and pharmacophore modelling. SAR QSAR Environ Res 2018,29(2),151-170","journal-title":"SAR QSAR Environ Res"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/1573409911666150702101559","volume":"11","author":"Nandi S.","year":"2015","unstructured":"Nandi S.; Bagchi M.C.; QSAR of chalcones utilizing theoretical molecular descriptors. Curr Comput Aided Drug Des 2015,11(2),184-193","journal-title":"Curr Comput Aided Drug Des"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cbdd.13388","volume":"93","author":"Muhammed M.T.","year":"2019","unstructured":"Muhammed M.T.; Aki-Yalcin E.; Homology modeling in drug discovery: Overview, current applications, and future perspectives. Chem Biol Drug Des 2019,93(1),12-20","journal-title":"Chem Biol Drug Des"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/0250-474X.102537","volume":"74","author":"Vyas V.K.","year":"2012","unstructured":"Vyas V.K.; Ukawala R.D.; Ghate M.; Chintha C.; Homology modeling a fast tool for drug discovery: current perspectives. Indian J Pharm Sci 2012,74(1),1-17","journal-title":"Indian J Pharm Sci"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3389\/fphar.2018.00923","volume":"9","author":"Salmaso V.","year":"2018","unstructured":"Salmaso V.; Moro S.; Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: an overview. Front Pharmacol 2018,9,923","journal-title":"Front Pharmacol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"Ferreira L.G.","year":"2015","unstructured":"Ferreira L.G.; Dos Santos R.N.; Oliva G.; Andricopulo A.D.; Molecular docking and structure-based drug design strategies. Molecules 2015,20(7),13384-13421","journal-title":"Molecules"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40484-019-0172-y","volume":"7","author":"Fan J.","year":"2019","unstructured":"Fan J.; Fu A.; Zhang L.; Progress in molecular docking. Quant Biol 2019,7,83-89","journal-title":"Quant Biol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2174\/1389450119666181022153016","volume":"20","author":"Saikia S.","year":"2019","unstructured":"Saikia S.; Bordoloi M.; Molecular docking: challenges, advances and its use in drug discovery perspective. Curr Drug Targets 2019,20(5),501-521","journal-title":"Curr Drug Targets"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/1871530319666181128100903","volume":"19","author":"Panwar U.","year":"2019","unstructured":"Panwar U.; Singh S.K.; Identification of novel pancreatic lipase inhibitors using in silico studies. Endocr Metab Immune Disord Drug Targets 2019,19(4),449-457","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.2174\/09298673113209990001","volume":"20","author":"Lavecchia A.","year":"2013","unstructured":"Lavecchia A.; Di Giovanni C.; Virtual screening strategies in drug discovery: a critical review. Curr Med Chem 2013,20(23),2839-2860","journal-title":"Curr Med Chem"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3389\/fphar.2018.01275","volume":"9","author":"Neves B.J.","year":"2018","unstructured":"Neves B.J.; Braga R.C.; Melo-Filho C.C.; Moreira-Filho J.T.; Muratov E.N.; Andrade C.H.; QSAR-based virtual screening: advances and applications in drug discovery. Front Pharmacol 2018,9,1275","journal-title":"Front Pharmacol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.drudis.2010.03.013","volume":"15","author":"Yang S.Y.","year":"2010","unstructured":"Yang S.Y.; Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 2010,15(11-12),444-450","journal-title":"Drug Discov Today"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2174\/0929867013372481","volume":"8","author":"Kurogi Y.","year":"2001","unstructured":"Kurogi Y.; G\u00fcner O.F.; Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr Med Chem 2001,8(9),1035-1055","journal-title":"Curr Med Chem"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3389\/fphar.2018.01275","volume":"9","author":"Neves B.J.","year":"2018","unstructured":"Neves B.J.; Braga R.C.; Melo-Filho C.C.; Moreira-Filho J.T.; Muratov E.N.; Andrade C.H.; QSAR-based virtual screening: advances and applications in drug discovery. Front Pharmacol 2018,9,1275","journal-title":"Front Pharmacol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/156802610790232260","volume":"10","author":"Verma J.","year":"2010","unstructured":"Verma J.; Khedkar V.M.; Coutinho E.C.; 3D-QSAR in drug design--a review. Curr Top Med Chem 2010,10(1),95-115","journal-title":"Curr Top Med Chem"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1021\/bk-1999-0719.ch014","volume":"719","author":"Heritage T.W.","year":"1999","unstructured":"Heritage T.W.; Lowis D.R.; ACS Symp Ser 1999,719,212-25","journal-title":"ACS Symp Ser"},{"key":"ref=140","first-page":"1","author":"Chavda J.","year":"2019","unstructured":"Chavda J.; Bhatt H.; 3D-QSAR (CoMFA, CoMSIA, HQSAR and topomer CoMFA), MD simulations and molecular docking studies on purinylpyridine derivatives as B-Raf inhibitors for the treatment of melanoma cancer 2019,1-5","journal-title":"3D-QSAR (CoMFA, CoMSIA, HQSAR and topomer CoMFA), MD simulations and molecular docking studies on purinylpyridine derivatives as B-Raf inhibitors for the treatment of melanoma cancer"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.1021\/ja00226a005","volume":"110","author":"Cramer R.D.","year":"1988","unstructured":"Cramer R.D.; Patterson D.E.; Bunce J.D.; Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988,110(18),5959-5967","journal-title":"J Am Chem Soc"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1080\/07391102.2017.1384400","volume":"36","author":"Panwar U.","year":"2018","unstructured":"Panwar U.; Singh S.K.; Structure-based virtual screening toward the discovery of novel inhibitors for impeding the protein-protein interaction between HIV-1 integrase and human lens epithelium-derived growth factor (LEDGF\/p75). J Biomol Struct Dyn 2018,36(12),3199-3217","journal-title":"J Biomol Struct Dyn"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1021\/acs.jcim.8b00737","volume":"59","author":"van Hilten N.","year":"2019","unstructured":"van Hilten N.; Chevillard F.; Kolb P.; Virtual compound libraries in computer-assisted drug discovery. J Chem Inf Model 2019,59(2),644-651","journal-title":"J Chem Inf Model"},{"key":"ref=144","unstructured":"ScienceDaily [homepage on the Internet] Learning from nature's bounty: New libraries for drug discovery. Available from:"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.2174\/1568026614666140929124445","volume":"14","author":"Lionta E.","year":"2014","unstructured":"Lionta E.; Spyrou G.; Vassilatis D.K.; Cournia Z.; Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem 2014,14,1923-1938","journal-title":"Curr Top Med Chem"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sbi.2017.10.010","volume":"48","author":"\u015aled\u017a P.","year":"2018","unstructured":"\u015aled\u017a P.; Caflisch A.; Protein structure-based drug design: from docking to molecular dynamics. Curr Opin Struct Biol 2018,48,93-102","journal-title":"Curr Opin Struct Biol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.3762\/bjoc.12.267","volume":"12","author":"Leelananda S.P.","year":"2016","unstructured":"Leelananda S.P.; Lindert S.; Computational methods in drug discovery. Beilstein J Org Chem 2016,12,2694-2718","journal-title":"Beilstein J Org Chem"},{"key":"ref=148","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.72898","author":"Phillips MA","unstructured":"Phillips MA; Stewart MA; Woodling DL; Xie ZR; Has molecular docking ever brought us a medicine? IntechOpen","journal-title":"IntechOpen"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1042\/EBC20170052","volume":"61","author":"van Montfort R.L.M.","year":"2017","unstructured":"van Montfort R.L.M.; Workman P.; Structure-based drug design: aiming for a perfect fit. Essays Biochem 2017,61(5),431-437","journal-title":"Essays Biochem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/ijms17060819","volume":"17","author":"Hu G.","year":"2016","unstructured":"Hu G.; Ma A.; Dou X.; Zhao L.; Wang J.; Computational studies of a mechanism for binding and drug resistance in the wild type and four mutations of HIV-1 protease with a GRL-0519 inhibitor. Int J Mol Sci 2016,17(6),819","journal-title":"Int J Mol Sci"},{"key":"ref=151","first-page":"95","volume":"7","author":"Lv Z.","year":"2015","unstructured":"Lv Z.; Chu Y.; Wang Y.; HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl) 2015,7,95-104","journal-title":"HIV AIDS (Auckl)"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00003495-200969040-00007","volume":"69","author":"McKeage K.","year":"2009","unstructured":"McKeage K.; Perry C.M.; Keam S.J.; Darunavir: a review of its use in the management of HIV infection in adults. Drugs 2009,69(4),477-503","journal-title":"Drugs"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","volume":"59","author":"Ghosh A.K.","year":"2016","unstructured":"Ghosh A.K.; Osswald H.L.; Prato G.; Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS. J Med Chem 2016,59(11),5172-5208","journal-title":"J Med Chem"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1080\/13543784.2016.1212837","volume":"25","author":"Midde N.M.","year":"2016","unstructured":"Midde N.M.; Patters B.J.; Rao P.; Cory T.J.; Kumar S.; Investigational protease inhibitors as antiretroviral therapies. Expert Opin Investig Drugs 2016,25(10),1189-1200","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1752-153X-7-88","volume":"7","author":"Ul-Haq Z.","year":"2013","unstructured":"Ul-Haq Z.; Usmani S.; Shamshad H.; Mahmood U.; Halim S.A.; A combined 3D-QSAR and docking studies for the in-silico prediction of HIV-protease inhibitors. Chem Cent J 2013,7(1),88","journal-title":"Chem Cent J"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/1062936X.2013.772919","volume":"24","author":"Reddy K.K.","year":"2013","unstructured":"Reddy K.K.; Singh S.K.; Tripathi S.K.; Selvaraj C.; Identification of potential HIV-1 integrase strand transfer inhibitors: in silico virtual screening and QM\/MM docking studies. SAR QSAR Environ Res 2013,24(7),581-595","journal-title":"SAR QSAR Environ Res"},{"key":"ref=157","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2018-0060","volume":"4","author":"Choi E.","year":"2018","unstructured":"Choi E.; Mallareddy J.R.; Lu D.; Kolluru S.; Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase. Future Sci OA 2018,4(9)","journal-title":"Future Sci OA"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1021\/ci300541c","volume":"53","author":"Xue W.","year":"2013","unstructured":"Xue W.; Jin X.; Ning L.; Wang M.; Liu H.; Yao X.; Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. J Chem Inf Model 2013,53(1),210-222","journal-title":"J Chem Inf Model"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nsmb.2485","volume":"20","author":"Lapkouski M.","year":"2013","unstructured":"Lapkouski M.; Tian L.; Miller J.T.; Le Grice S.F.J.; Yang W.; Complexes of HIV-1 RT, NNRTI and RNA\/DNA hybrid reveal a structure compatible with RNA degradation. Nat Struct Mol Biol 2013,20(2),230-236","journal-title":"Nat Struct Mol Biol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1208\/s12248-014-9604-9","volume":"16","author":"Gu W.G.","year":"2014","unstructured":"Gu W.G.; Zhang X.; Yuan J.F.; Anti-HIV drug development through computational methods. AAPS J 2014,16(4),674-680","journal-title":"AAPS J"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"E802","DOI":"10.1073\/pnas.1717932115","volume":"115","author":"Kudalkar S.N.","year":"2018","unstructured":"Kudalkar S.N.; Beloor J.; Quijano E.; From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proc Natl Acad Sci USA 2018,115(4),E802-E811","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/v11050408","volume":"11","author":"Cherne M.D.","year":"2019","unstructured":"Cherne M.D.; Hall J.; Kellner A.; Chong C.F.; Cole A.L.; Cole A.M.; Avirulins, a novel class of HIV-1 reverse transcriptase inhibitors effective in the female reproductive tract mucosa. Viruses 2019,11(5),408","journal-title":"Viruses"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1590\/0074-02760150239","volume":"110","author":"Santos L.H.","year":"2015","unstructured":"Santos L.H.; Ferreira R.S.; Caffarena E.R.; Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors. Mem Inst Oswaldo Cruz 2015,110(7),847-864","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=164","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.201800159","volume":"15","author":"Mostashari Rad T.","year":"2018","unstructured":"Mostashari Rad T.; Saghaie L.; Fassihi A.; HIV-1 entry inhibitors: a review of experimental and computational studies. Chem Biodivers 2018,15(10)","journal-title":"Chem Biodivers"},{"key":"ref=165","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007161","volume":"2","author":"Arts E.J.","year":"2012","unstructured":"Arts E.J.; Hazuda D.J.; HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012,2(4)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"376","DOI":"10.4081\/oncol.2019.376","volume":"13","author":"Chirkut S.","year":"2019","unstructured":"Chirkut S.; Breast cancer, human immunodeficiency virus and highly active antiretroviral treatment; implications for a high-rate seropositive region. Oncol Rev 2019,13(1),376","journal-title":"Oncol Rev"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11904-011-0076-6","volume":"8","author":"Hull M.W.","year":"2011","unstructured":"Hull M.W.; Montaner J.; Antiretroviral therapy: a key component of a comprehensive HIV prevention strategy. Curr HIV\/AIDS Rep 2011,8(2),85-93","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/IDR.S146584","volume":"10","author":"Tsai H.C.","year":"2017","unstructured":"Tsai H.C.; Chen I.T.; Wu K.S.; High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009-2014. Infect Drug Resist 2017,10,343-352","journal-title":"Infect Drug Resist"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/HIV.S52266","volume":"6","author":"Oshikoya K.A.","year":"2014","unstructured":"Oshikoya K.A.; Oreagba I.A.; Lawal S.; Potential drug-drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria. HIV AIDS (Auckl) 2014,6,49-59","journal-title":"HIV AIDS (Auckl)"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/09540121.2015.1074653","volume":"28","author":"Buell K.G.","year":"2016","unstructured":"Buell K.G.; Chung C.; Chaudhry Z.; Puri A.; Nawab K.; Ravindran R.P.; Lifelong antiretroviral therapy or HIV cure: The benefits for the individual patient. AIDS Care 2016,28(2),242-246","journal-title":"AIDS Care"},{"key":"ref=171","doi-asserted-by":"publisher","DOI":"10.4081\/idr.2013.s1.e5","volume":"5","author":"Pennings P.S.","year":"2013","unstructured":"Pennings P.S.; HIV drug resistance: problems and perspectives. Infect Dis Rep 2013,5(Suppl. 1)","journal-title":"Infect Dis Rep"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4103\/0253-7613.96296","volume":"44","author":"Desai M.","year":"2012","unstructured":"Desai M.; Iyer G.; Dikshit R.K.; Antiretroviral drugs: critical issues and recent advances. Indian J Pharmacol 2012,44(3),288-298","journal-title":"Indian J Pharmacol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/COH.0000000000000527","volume":"14","author":"Vitoria M.","year":"2019","unstructured":"Vitoria M.; Rangaraj A.; Ford N.; Doherty M.; Current and future priorities for the development of optimal HIV drugs. Curr Opin HIV AIDS 2019,14(2),143-149","journal-title":"Curr Opin HIV AIDS"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/174816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T13:56:39Z","timestamp":1695218199000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/174816\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":173,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2019,11,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190911160244","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}